Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

TNM classification and the need for revision of pN3a breast cancer.

van Nijnatten TJA, Moossdorff M, de Munck L, Goorts B, Vane MLG, Keymeulen KBMI, Beets-Tan RGH, Lobbes MBI, Smidt ML.

Eur J Cancer. 2017 Jul;79:23-30. doi: 10.1016/j.ejca.2017.04.002.

PMID:
28458119
2.

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

Elshof LE, Schaapveld M, Rutgers EJ, Schmidt MK, de Munck L, van Leeuwen FE, Wesseling J.

Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.

3.

Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.

van Nijnatten TJ, Simons JM, Moossdorff M, de Munck L, Lobbes MB, van der Pol CC, Koppert LB, Luiten EJ, Smidt ML.

Breast Cancer Res Treat. 2017 May;163(1):159-166. doi: 10.1007/s10549-017-4157-0. Epub 2017 Feb 17.

4.

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.

Goorts B, van Nijnatten TJ, de Munck L, Moossdorff M, Heuts EM, de Boer M, Lobbes MB, Smidt ML.

Breast Cancer Res Treat. 2017 May;163(1):83-91. doi: 10.1007/s10549-017-4155-2. Epub 2017 Feb 15.

5.

Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?

Habraken V, van Nijnatten TJ, de Munck L, Moossdorff M, Heuts EM, Lobbes MB, Smidt ML.

Breast Cancer Res Treat. 2017 Feb;161(3):483-489. doi: 10.1007/s10549-016-4071-x. Epub 2016 Dec 3.

6.

Breast-conserving therapy versus mastectomy in T1-2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients.

van Maaren MC, de Munck L, Jobsen JJ, Poortmans P, de Bock GH, Siesling S, Strobbe LJA.

Breast Cancer Res Treat. 2016 Dec;160(3):511-521. doi: 10.1007/s10549-016-4012-8. Epub 2016 Oct 11.

PMID:
27730424
7.

Catalytic Enantioselective Aza-Reformatsky Reaction with Cyclic Imines.

De Munck L, Vila C, Muñoz MC, Pedro JR.

Chemistry. 2016 Dec 5;22(49):17590-17594. doi: 10.1002/chem.201604606. Epub 2016 Oct 24.

PMID:
27775191
8.

Digital vs screen-film mammography in population-based breast cancer screening: performance indicators and tumour characteristics of screen-detected and interval cancers.

de Munck L, de Bock GH, Otter R, Reiding D, Broeders MJ, Willemse PH, Siesling S.

Br J Cancer. 2016 Aug 23;115(5):517-24. doi: 10.1038/bjc.2016.226. Epub 2016 Aug 4.

PMID:
27490807
9.

10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.

van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, Poortmans P, Strobbe LJ, Siesling S.

Lancet Oncol. 2016 Aug;17(8):1158-70. doi: 10.1016/S1470-2045(16)30067-5. Epub 2016 Jun 22.

PMID:
27344114
10.

Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly.

van Rooijen JM, de Munck L, Teeuwen GM, de Graaf JC, Jansman FG, Boers JE, Siesling S.

Anticancer Drugs. 2016 Feb;27(2):127-32. doi: 10.1097/CAD.0000000000000310.

PMID:
26473525
11.

Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.

de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S.

Br J Haematol. 2015 Dec;171(5):720-5. doi: 10.1111/bjh.13653. Epub 2015 Sep 11.

PMID:
26358087
12.

Hormone receptors as a marker of poor survival in epithelial ovarian cancer.

van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hospers G, Reyners A.

Gynecol Oncol. 2015 Sep;138(3):634-9. doi: 10.1016/j.ygyno.2015.06.032. Epub 2015 Jun 24.

PMID:
26115976
13.

Enantioselective alkynylation of benzo[e][1,2,3]-oxathiazine 2,2-dioxides catalysed by (R)-VAPOL-Zn complexes: synthesis of chiral propargylic cyclic sulfamidates.

De Munck L, Monleón A, Vila C, Muñoz MC, Pedro JR.

Org Biomol Chem. 2015 Jul 21;13(27):7393-6. doi: 10.1039/c5ob01012h.

PMID:
26081255
14.

Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment.

van der Heiden-van der Loo M, de Munck L, Sonke GS, van Dalen T, van Diest PJ, van den Bongard HJ, Peeters PH, Rutgers EJ.

Eur J Cancer. 2015 May;51(8):915-21. doi: 10.1016/j.ejca.2015.03.014. Epub 2015 Apr 6.

PMID:
25857549
15.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators.

JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.

PMID:
24825642
16.

Breast cancer screening halves the risk of breast cancer death: a case-referent study.

Paap E, Verbeek AL, Botterweck AA, van Doorne-Nagtegaal HJ, Imhof-Tas M, de Koning HJ, Otto SJ, de Munck L, van der Steen A, Holland R, den Heeten GJ, Broeders MJ.

Breast. 2014 Aug;23(4):439-44. doi: 10.1016/j.breast.2014.03.002. Epub 2014 Apr 6.

PMID:
24713277
17.

Quality improvement by implementing an integrated oncological care pathway for breast cancer patients.

van Hoeve J, de Munck L, Otter R, de Vries J, Siesling S.

Breast. 2014 Aug;23(4):364-70. doi: 10.1016/j.breast.2014.01.008. Epub 2014 Feb 25.

PMID:
24582455
18.

Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.

van Rooijen JM, de Munck L, de Graaf JC, Siesling S, de Vries EG, Boers JE.

Eur J Cancer. 2014 Mar;50(5):885-91. doi: 10.1016/j.ejca.2014.01.010. Epub 2014 Jan 31.

PMID:
24491395
19.

Attending the breast screening programme after breast cancer treatment: a population-based study.

de Munck L, Kwast A, Reiding D, de Bock GH, Otter R, Willemse PH, Siesling S.

Cancer Epidemiol. 2013 Dec;37(6):968-72. doi: 10.1016/j.canep.2013.09.003. Epub 2013 Sep 26.

PMID:
24075800
20.

Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients.

Bantema-Joppe EJ, van den Heuvel ER, de Munck L, de Bock GH, Smit WG, Timmer PR, Dolsma WV, Jansen L, Schröder CP, Siesling S, Langendijk JA, Maduro JH.

Breast Cancer Res Treat. 2013 Aug;140(3):577-85. doi: 10.1007/s10549-013-2650-7. Epub 2013 Aug 3.

PMID:
23912958

Supplemental Content

Loading ...
Support Center